A patented luteolin pharmaceutical composition from the USA has reported that the luteolin formulation prevents and treats the cancerous cells of liver, brain, pancreas, lung, breast cancer, and leukemia via targeting the BCL-2, bromodomains, sirtuins, kinases, and matrix metalloproteinases [154]. The gene discussed is BCL2; the disease is breast carcinoma.